胰岛素抵抗指标TyG对心肌梗死后残余风险的增量效应
Incremental Effect of TyG, an Indicator of Insulin Resistance, on Residual Risk after Myocardial Infarction
摘要: 目的:本研究的目的是为了研究TyG与心肌梗死患者残余风险之间的关系。方法:选取712名急性心肌梗的患者进行5年随访,采集患者基本信息、体格检查等资料,检测实验室相关指标。绘制ROC曲线评估TyG对残余风险的预测能力,使用R语言计算分析净重分类指数(NRI)和综合判别改善指数(IDI),以进一步评估TyG在心肌梗死后残余风险传统危险因素之上的额外预测价值。结果:ROC曲线显示,TyG指数曲线下面积0.554 (95%CI: 0.503~0.604, P = 0.042),在基线风险模型中纳入TyG的综合判别改善指数[IDI]:0.0082,P = 0.022;纳入TyG的净重新分类指数[NRI]:0.2169,P = 0.017。在基线风险模型中纳入TyG对基线模型对MACE的预测能力有增量效应。结论:TyG对心血管残余风险具有一定的预测能力,在控制传统危险因素的同时,TyG可以指导急性心梗患者的进一步强化治疗。
Abstract: Objective: The purpose of this study was to investigate the relationship between TyG and residual risk in patients with myocardial infarction. Methods: 712 patients with acute myocardial infarction were selected for 5-year follow-up, and basic information, physical examination and other data were collected, and laboratory related indexes were tested. ROC curves were plotted to assess the predictive ability of TyG on residual risk. The net reclassification index (NRI) and integrated discriminant improvement index (IDI) were calculated and analyzed using the R language to further assess the additional predictive value of TyG over and above the traditional risk factors for residual risk after myocardial infarction. Results: ROC curves showed an area under the curve of the TyG index of 0.554 (95% CI: 0.503 to 0.604, P = 0.042), a composite discriminant improvement index [IDI] incorporating TyG in the baseline risk model: 0.0082, P = 0.022, and a net reclassification index [NRI] incorporating TyG: 0.2169, P = 0.017. In the baseline risk model, the inclusion of TyG had an incremental effect on the predictive power of the baseline model for MACE. Conclusion: TyG has a predictive ability for residual cardiovascular risk, and while controlling traditional risk factors, TyG may guide further intensive treatment for patients with acute myocardial infarction.
文章引用:汪园园, 李鹏. 胰岛素抵抗指标TyG对心肌梗死后残余风险的增量效应[J]. 临床医学进展, 2025, 15(4): 1631-1636. https://doi.org/10.12677/acm.2025.1541101

参考文献

[1] Virani, S.S., Alonso, A., Benjamin, E.J., et al. (2020) Heart Disease and Stroke Statistics—2020 Update: A Report from the American Heart Association. Circulation, 141, e139-e596.
[2] Choi, S. (2019) The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers. Journal of Lipid and Atherosclerosis, 8, 173-182. [Google Scholar] [CrossRef] [PubMed]
[3] Rosenblit, P.D. (2019) Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. Current Diabetes Reports, 19, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[4] Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al. (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 372, 2387-2397. [Google Scholar] [CrossRef] [PubMed]
[5] Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 376, 1713-1722. [Google Scholar] [CrossRef] [PubMed]
[6] Di Pino, A. and DeFronzo, R.A. (2019) Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocrine Reviews, 40, 1447-1467. [Google Scholar] [CrossRef] [PubMed]
[7] Beverly, J.K. and Budoff, M.J. (2019) Atherosclerosis: Pathophysiology of Insulin Resistance, Hyperglycemia, Hyperlipidemia, and Inflammation. Journal of Diabetes, 12, 102-104. [Google Scholar] [CrossRef] [PubMed]
[8] Bornfeldt, K.E. and Tabas, I. (2011) Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metabolism, 14, 575-585. [Google Scholar] [CrossRef] [PubMed]
[9] Khan, S.H., Sobia, F., Niazi, N.K., Manzoor, S.M., Fazal, N. and Ahmad, F. (2018) Metabolic Clustering of Risk Factors: Evaluation of Triglyceride-Glucose Index (TyG Index) for Evaluation of Insulin Resistance. Diabetology & Metabolic Syndrome, 10, Article No. 74. [Google Scholar] [CrossRef] [PubMed]
[10] Li, S., Guo, B., Chen, H., Shi, Z., Li, Y., Tian, Q., et al. (2019) The Role of the Triglyceride (Triacylglycerol) Glucose Index in the Development of Cardiovascular Events: A Retrospective Cohort Analysis. Scientific Reports, 9, Article No. 7320. [Google Scholar] [CrossRef] [PubMed]
[11] Sánchez-Íñigo, L., Navarro-González, D., Fernández-Montero, A., Pastrana-Delgado, J. and Martínez, J.A. (2016) The Tyg Index May Predict the Development of Cardiovascular Events. European Journal of Clinical Investigation, 46, 189-197. [Google Scholar] [CrossRef] [PubMed]
[12] Su, W., Chen, S., Huang, Y., Huang, J., Wu, P., Hsu, W., et al. (2019) Comparison of the Effects of Fasting Glucose, Hemoglobin A1c, and Triglyceride-Glucose Index on Cardiovascular Events in Type 2 Diabetes Mellitus. Nutrients, 11, Article 2838. [Google Scholar] [CrossRef] [PubMed]
[13] Barzegar, N., Tohidi, M., Hasheminia, M., Azizi, F. and Hadaegh, F. (2020) The Impact of Triglyceride-Glucose Index on Incident Cardiovascular Events during 16 Years of Follow-Up: Tehran Lipid and Glucose Study. Cardiovascular Diabetology, 19, Article No. 155. [Google Scholar] [CrossRef] [PubMed]
[14] Hong, S., Han, K. and Park, C. (2020) The Triglyceride Glucose Index Is a Simple and Low-Cost Marker Associated with Atherosclerotic Cardiovascular Disease: A Population-Based Study. BMC Medicine, 18, Article No. 361. [Google Scholar] [CrossRef] [PubMed]
[15] Park, B., Lee, Y., Lee, H.S. and Jung, D. (2020) The Triglyceride-Glucose Index Predicts Ischemic Heart Disease Risk in Koreans: A Prospective Study Using National Health Insurance Service Data. Cardiovascular Diabetology, 19, Article No. 210. [Google Scholar] [CrossRef] [PubMed]
[16] Tian, X., Zuo, Y., Chen, S., Liu, Q., Tao, B., Wu, S., et al. (2021) Triglyceride-Glucose Index Is Associated with the Risk of Myocardial Infarction: An 11-Year Prospective Study in the Kailuan Cohort. Cardiovascular Diabetology, 20, Article No. 19. [Google Scholar] [CrossRef] [PubMed]
[17] Alizargar, J., Bai, C., Hsieh, N. and Wu, S.V. (2020) Use of the Triglyceride-Glucose Index (TyG) in Cardiovascular Disease Patients. Cardiovascular Diabetology, 19, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[18] Lee, E.Y., Yang, H.K., Lee, J., Kang, B., Yang, Y., Lee, S., et al. (2016) Triglyceride Glucose Index, a Marker of Insulin Resistance, Is Associated with Coronary Artery Stenosis in Asymptomatic Subjects with Type 2 Diabetes. Lipids in Health and Disease, 15, Article No. 155. [Google Scholar] [CrossRef] [PubMed]
[19] Shi, W., Xing, L., Jing, L., Tian, Y., Yan, H., Sun, Q., et al. (2020) Value of Triglyceride-Glucose Index for the Estimation of Ischemic Stroke Risk: Insights from a General Population. Nutrition, Metabolism and Cardiovascular Diseases, 30, 245-253. [Google Scholar] [CrossRef] [PubMed]
[20] Wheatcroft, S.B., Williams, I.L., Shah, A.M. and Kearney, M.T. (2003) Pathophysiological Implications of Insulin Resistance on Vascular Endothelial Function. Diabetic Medicine, 20, 255-268. [Google Scholar] [CrossRef] [PubMed]
[21] Guerrero-Romero, F., Simental-Mendía, L.E., González-Ortiz, M., Martínez-Abundis, E., Ramos-Zavala, M.G., Hernández-González, S.O., et al. (2010) The Product of Triglycerides and Glucose, a Simple Measure of Insulin Sensitivity. Comparison with the Euglycemic-Hyperinsulinemic Clamp. The Journal of Clinical Endocrinology & Metabolism, 95, 3347-3351. [Google Scholar] [CrossRef] [PubMed]